Tao Fu, M.S., MBA

Tao is a Venture Partner on the Frazier Life Sciences team and has over 25 years of experience in the pharmaceutical and biotech industry.

Tao joined the Frazier Life Sciences team as a Venture Partner in 2022. He currently serves as the President and CEO of Attovia Therapeutics, a FLS portfolio company. Tao has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry.

Prior to joining Frazier Tao served as President & Chief Operating Officer and then Chief Strategy Officer for Zai Lab, a publicly traded biotech company listed on both NASDAQ (ZLAB) and Hong Kong. He joined Zai Lab in 2018, holding a broad set of responsibilities including strategy, operations, business development, CMC, quality, and other corporate functions. Previously from 2015 to 2018, Tao was Executive Vice President, Chief Commercial and Business Officer of Portola Pharmaceuticals (PTLA), a publicly traded biotech company specializing in cardiovascular disease and cancer. In this role, Tao led Portola’s commercial operations, marketing, sales, and business development. From 2014 to 2015, Tao was Vice President, Head of M&A and Alliance Management at Bristol Myers-Squibb (BMS), leading the company’s corporate development, alliance management and venture capital investing activities. Prior to BMS, Tao worked at Johnson & Johnson (J&J) for 11 years, holding a number of leadership positions with increasing responsibilities, most recently as Vice President, Head of M&A, responsible for J&J’s global M&A activities in pharmaceuticals. Earlier in his career, Tao worked at Scios Inc., a biotech company in California and McKinsey & Company.

Tao received an MS in biology from the University of Rochester, and an MBA in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University and is a Chartered Financial Analyst (CFA).